Lancet Regional Health-Europe最新文献

{"title":"Prioritising meaningful outcomes in the practice evaluation of new chlamydia testing guidelines","authors":"Zoïe W. Alexiou , Nicole H.T.M. Dukers-Muijrers","doi":"10.1016/j.lanepe.2025.101579","DOIUrl":"10.1016/j.lanepe.2025.101579","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101579"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new path for assisted dying in Europe: France's middle way","authors":"The Lancet Regional Health – Europe","doi":"10.1016/j.lanepe.2026.101617","DOIUrl":"10.1016/j.lanepe.2026.101617","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101617"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146144483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of adults with community-acquired bacterial meningitis in the Netherlands: a prospective nationwide cohort study","authors":"Evelien H.G.M. Drost,&nbsp;Eva N. Schepers,&nbsp;Nora Chekrouni,&nbsp;Thijs M. van Soest,&nbsp;Diederik L.H. Koelman,&nbsp;Merijn W. Bijlsma,&nbsp;Matthijs C. Brouwer,&nbsp;Diederik van de Beek","doi":"10.1016/j.lanepe.2025.101529","DOIUrl":"10.1016/j.lanepe.2025.101529","url":null,"abstract":"<div><h3>Background</h3><div>Bacterial meningitis is associated with high rates of unfavourable outcome. We conducted a nationwide prospective study in the Netherlands to evaluate outcome in adults with bacterial meningitis, focusing on pathogen-specific differences, risk factors for unfavourable outcomes, and neurological sequelae.</div></div><div><h3>Methods</h3><div>Adult patients with community-acquired bacterial meningitis confirmed by lumbar puncture were identified through the database of the Netherlands Reference Laboratory for Bacterial Meningitis and prospectively included. Neurological examinations were performed on admission and discharge by the treating physician, and outcome was assessed using the Glasgow Outcome Scale, with scores of 1–4 classified as unfavourable. Logistic regression was used to evaluate the association between potential predictors and outcome.</div></div><div><h3>Findings</h3><div>Between January 1, 2006 and January 1, 2024, 2974 patients were included. <em>Streptococcus pneumoniae</em> was the most common pathogen (2029/2974; 68%), followed by <em>Neisseria meningitidis</em> (329/2974; 11%), <em>Listeria monocytogenes</em> (182/2974; 6%), <em>Haemophilus influenzae</em> (119/2974; 4%) and <em>Streptococcus pyogenes</em> (83/2974; 3%). Overall mortality was 17% (516/2974) and remained stable over 18 years (odds ratio per admission year 0·99 [95% CI 0·97–1·01]). Mortality was highest for <em>L</em>. <em>monocytogenes</em> (58/182; 32%), <em>S</em>. <em>pyogenes</em> (16/83; 19%), and <em>S</em>. <em>pneumoniae</em> (365/2029; 18%). Unfavourable outcome occurred in 1161/2974 patients (39%; 95% CI 37–41), and key predictors included advanced age, prolonged symptom duration, systemic or cerebral compromise, low CSF white-cell counts, and absence of adjunctive dexamethasone. Among survivors, neurological sequelae occurred in 1146/2088 patients (55%), including hearing impairment (692/2197; 31%) and cognitive impairment (481/2108; 23%), with highest rates following <em>S</em>. <em>pneumoniae</em> (881/1419; 62%), and <em>S</em>. <em>pyogenes</em> (44/59; 75%).</div></div><div><h3>Interpretation</h3><div>Mortality and morbidity from bacterial meningitis remain high, especially in <em>L</em>. <em>monocytogenes</em>, <em>S</em>. <em>pyogenes</em>, and <em>S</em>. <em>pneumoniae</em> infections. These findings highlight an urgent need for enhanced vaccination strategies, timely recognition, and improved therapies.</div></div><div><h3>Funding</h3><div>Netherlands Organization for Health Research and Development (ZonMW).</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101529"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145499912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexually transmitted infection testing and key outcomes following implementation of online postal self-sampling into sexual health services in England: a retrospective observational study of routinely collected service-level healthcare data","authors":"Jo Gibbs ,&nbsp;Oliver Stirrup ,&nbsp;Anna Tostevin ,&nbsp;Alison Howarth ,&nbsp;Claire Dewsnap ,&nbsp;Jonathan D.C. Ross ,&nbsp;Andy Williams ,&nbsp;Vicky Tittle ,&nbsp;Sara Day ,&nbsp;Jack Brown ,&nbsp;David Crundwell ,&nbsp;Louise J. Jackson ,&nbsp;Catherine H. Mercer ,&nbsp;Jessica Sheringham ,&nbsp;Ann Sullivan ,&nbsp;Andrew J. Winter ,&nbsp;Geoff Wong ,&nbsp;Andrew Copas ,&nbsp;Fiona Burns","doi":"10.1016/j.lanepe.2025.101541","DOIUrl":"10.1016/j.lanepe.2025.101541","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;A shift to online postal self-sampling (OPSS) for sexually transmitted infections (STIs) in high-income settings has occurred. We evaluate whether introduction of OPSS in England is associated with changes in testing activity and if this differs by population characteristics.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A retrospective study of sexual health (online and clinic-based) service-level data, across three case study areas (CSAs) that implemented OPSS at different times, using different models, and whose populations have different socio-demographic profiles, between 01/01/2015 and 31/12/2022 (from 01/08/2014 in CSA1 to ensure 12 months pre-OPSS). The primary outcome was chlamydia/gonorrhoea and HIV testing activity. We evaluated change over time using selected calendar years, with total activity following introduction of OPSS (2019 and 2022) compared to pre-OPSS periods (CSA1, 2014–2015, CSA2 2017, CSA3 2019), and whether outcome changes differed by socio-demographic characteristics.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;In all CSAs chlamydia/gonorrhoea and HIV testing activity increased following introduction of OPSS with incidence rate ratios (IRR) for chlamydia/gonorrhoea testing in 2022 compared to pre-OPSS baseline ranging from 2.1 (95% CI 2.1–2.2) in CSA1 to 2.5 (95% CI 2.4–2.5) in CSA3, and for HIV testing from 1.5 (95% CI 1.5–1.5) in CSA1 to 2.8 (95% CI 2.8–2.8) in CSA2. Differences existed across all demographic characteristics in the relative change in testing incidence (all P &lt; 0.0001 for chlamydia/gonorrhoea). Higher testing activity via OPSS was seen among men who have sex with men (MSM), particularly in CSAs1-2 for chlamydia/gonorrhoea (IRR2.9 (95% CI 2.8–3.1) and 3.6 (95% CI 3.5–3.7) in MSM compared to 1.7 (95% CI 1.7–1.8)and 1.8 (95% CI 1.8–1.8) in men who have sex exclusively with women (MSEW) for 2022 &lt;em&gt;vs&lt;/em&gt; pre-OPSS). In CSA3, the largest relative increase occurred in women (IRR 3.2 (95% CI 3.1–3.3), compared to IRR 1.9 (95% CI 1.8–1.9) in MSEW). The most deprived areas had the lowest relative increase in chlamydia/gonorrhoea testing uptake (1.9–2.1 for CSA1-3).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;Despite a reduction in clinic-based testing linked to COVID-19, the introduction of OPSS has been associated with increases in overall testing activity. OPSS uptake was lower among populations with greater potential for unmet need, such as individuals living in more deprived areas. Although OPSS is available to all people living within the commissioned areas, in practice not all individuals with a need for STI testing are aware of it or have the confidence and ability to access it. Differences across all socio-demographic characteristics in the relative change in testing could inadvertently increase existing inequalities in access to care and it is important to offer choice of mode of testing for service users.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;&lt;span&gt;National Institute for Health and C","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101541"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conceptualising undervaccinated populations in high-income settings: why consensus and clarity matter","authors":"Sibylle Herzig van Wees ,&nbsp;Ben Kasstan-Dabush ,&nbsp;Michael J. Deml ,&nbsp;Ifrah Mohamed Ibrahim ,&nbsp;Sandra Mounier-Jack ,&nbsp;Michael Edelstein","doi":"10.1016/j.lanepe.2025.101586","DOIUrl":"10.1016/j.lanepe.2025.101586","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101586"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prioritising meaningful outcomes in the practice evaluation of new chlamydia testing guidelines—Authors’ reply","authors":"Lotte Werner ,&nbsp;Vita W. Jongen ,&nbsp;Sylvia M. Bruisten ,&nbsp;Maarten F. Schim van der Loeff ,&nbsp;Elske Hoornenborg ,&nbsp;Henry J.C. de Vries ,&nbsp;Janneke C.M. Heijne","doi":"10.1016/j.lanepe.2025.101580","DOIUrl":"10.1016/j.lanepe.2025.101580","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101580"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145938790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported, psychosocial and health economic outcomes in mild to moderate Friedreich's ataxia: baseline results of the PROFA study","authors":"Marcus Grobe-Einsler ,&nbsp;Stéphanie Borel ,&nbsp;Maresa Buchholz ,&nbsp;Sabrina Sayah ,&nbsp;Rania Hilab ,&nbsp;Lucie Pierron ,&nbsp;Audrey Iskandar ,&nbsp;Brittany Humphries ,&nbsp;Claire Ewenczyk ,&nbsp;Anna Heinzmann ,&nbsp;Mariana Atencio ,&nbsp;Katrin Feldmann ,&nbsp;Vivian Maas ,&nbsp;Jennifer Faber ,&nbsp;Sylvia Boesch ,&nbsp;Elisabetta Indelicato ,&nbsp;Kathrin Reetz ,&nbsp;Jörg B. Schulz ,&nbsp;Almut T. Bischoff ,&nbsp;Thomas Klopstock ,&nbsp;Bernhard Michalowsky","doi":"10.1016/j.lanepe.2025.101552","DOIUrl":"10.1016/j.lanepe.2025.101552","url":null,"abstract":"<div><h3>Background</h3><div>Friedreich ataxia (FA) is the most common autosomal recessive ataxia. Little attention has been paid to FA's impact on patient-reported, psychosocial, and health-economic outcomes. This study aimed to report these outcomes across FA's disability stages 1–5.</div></div><div><h3>Methods</h3><div>We assessed patients in Germany, France, and Austria as part of the PROFA study, a European multicenter observational study. The protocol included a study center visit followed by a remote mobile assessment capturing ataxia severity (SARA), daily living deficits (FARS-ADL), cognitive and affective impairments (CCAS), health-related quality of life (HRQoL: PROM-Ataxia short-form, EQ-5D-5L), mental well-being (WEMWBS), communication disabilities (COMATAX), and healthcare and informal care utilization. FARS disability stages were used to demonstrate outcomes with effect size measures (Eta-Squared, Cramér's V). Multivariate regression models evaluated associations between z-standardized outcomes and disability stages.</div></div><div><h3>Findings</h3><div>One hundred one patients (mean [SD]: age 35.0 [11.5]; GAA-repeat size 657 [299]; 50.5% women) were included. Activities of daily living, HRQoL, communication disabilities, and informal care utilization worsened significantly across disability stages with moderate to high effect sizes. Cognitive-affective impairments and mental well-being showed significant associations with small effect sizes. Twenty-three patients (33.3%) received formal care, while 40 (58.0%) received informal care (mean 12.2 h/week). Omaveloxolone was used by 33 patients (32.7%). Annual healthcare costs excluding Omaveloxolone were €13,620 (payer) and €32,679 (societal perspective, including informal care and productivity losses).</div></div><div><h3>Interpretation</h3><div>The results emphasize the multidimensional patient, societal, and economic burden of FA and the need for comprehensive care addressing physical, mental, and psychosocial health.</div></div><div><h3>Funding</h3><div><span>European Joint Programme on Rare Diseases</span> (EJP RD).</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101552"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145747382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in use of Attention-Deficit Hyperactivity Disorder medications among children and adults in five European countries, 2010 to 2023: a population-based observational study","authors":"Xintong Li ,&nbsp;Yuchen Guo ,&nbsp;Agustina Giuliodori Picco ,&nbsp;Anna Palomar-Cros ,&nbsp;Antonella Delmestri ,&nbsp;Wai Yi Man ,&nbsp;Isabella Kaczmarczyk ,&nbsp;James T. Brash ,&nbsp;Katia Verhamme ,&nbsp;Mees Mosseveld ,&nbsp;Talita Duarte-Salles ,&nbsp;Daniel Prieto-Alhambra ,&nbsp;Edward Burn","doi":"10.1016/j.lanepe.2025.101556","DOIUrl":"10.1016/j.lanepe.2025.101556","url":null,"abstract":"<div><h3>Background</h3><div>An increase in the use of medications for Attention-Deficit Hyperactivity Disorder (ADHD) has been reported globally. This study aims to estimate the trends of ADHD medications use among children and adults across Europe from 2010 to 2023.</div></div><div><h3>Methods</h3><div>We conducted a population-level observational study using electronic health records from five European countries: Belgium, Germany, the Netherlands, Spain, and the UK. We estimated the prevalence and incidence of methylphenidate, dexamphetamine, lisdexamfetamine, atomoxetine and guanfacine use among individuals aged 3 years and older. We used the proportion of patients covered to measure treatment adherence. All analyses were reported by country and stratified by age group and sex.</div></div><div><h3>Findings</h3><div>The prevalence of ADHD medication use increased across all five countries during the study period. Between 2010 and 2023, prevalence rose more than threefold in the UK (from 0.12% to 0.39%) and more than doubled in the Netherlands (from 0.67% to 1.56%). Adult use increased substantially in all countries, particularly among females. In the UK, prevalence among adults aged over 25 increased from 0.01% in 2010 to approximately 0.20% in 2023, representing a more than twenty-fold increase in females and fifteen-fold in males. Although ADHD medication use remained higher among males, the sex gap in treatment narrowed over time and with increasing age. After 1-year of medication initiation, 14.9%, 16.0%, 43.9%, and 30.8% of participants were covered by treatment in Germany, the Netherlands, Spain, and the UK respectively. Among initiators, the prevalence of psychiatric conditions and prior use of psycholeptic medications was higher in females and in older age groups.</div></div><div><h3>Interpretation</h3><div>Over 14 years, ADHD medication prevalence increased across Europe, with varying incidence trends by country, age, and sex. Understanding the utilisation of ADHD medications can provide useful information in monitoring use, as well as for anticipation and planning to minimise potential shortages.</div></div><div><h3>Funding</h3><div><span>European Medicines Agency</span>.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101556"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146144476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current perspectives on psychedelic treatments in Europe","authors":"Santiago Madero ,&nbsp;Oscar Soto-Angona ,&nbsp;Genis Ona ,&nbsp;Jose Sanchez-Moreno ,&nbsp;Eduard Vieta","doi":"10.1016/j.lanepe.2025.101537","DOIUrl":"10.1016/j.lanepe.2025.101537","url":null,"abstract":"<div><div>In this viewpoint, we explore the evolving landscape of psychedelic-assisted therapy in Europe, focusing on clinical, regulatory, and therapeutic developments. While access remains limited, recent initiatives in Switzerland, Germany, and the Czech Republic illustrate growing momentum toward regulated use. We examine the debate surrounding psychedelics as pharmacological agents versus psychotherapeutic catalysts and argue for an integrative framework that considers neurobiological mechanisms, subjective experience, and contextual factors. We focus on how their effects, particularly those involving neuroplasticity and critical periods, may interact with psychotherapeutic processes. We highlight the importance of context and psychological support in shaping outcomes and discuss the challenges of implementing scalable care models. Regulatory fragmentation and methodological complexities continue to hinder progress, but publicly funded trials such as EPIsoDE and PsyPal offer promising examples of ethical and effective approaches. In our view, the future of psychedelic therapy lies not in simplifying its complexity, but in embracing it.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101537"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145580505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strengthening non-communicable diseases monitoring systems in Europe through a multistakeholder collaborative approach: a key priority for advancing data-driven policymaking","authors":"Benedetta Armocida ,&nbsp;Hanna Tolonen ,&nbsp;Ivo Rakovac ,&nbsp;Beatrice Formenti ,&nbsp;Jill Farrington ,&nbsp;Allison Ekberg ,&nbsp;Hector Bueno ,&nbsp;Giovanni Capelli ,&nbsp;Silvia Francisci ,&nbsp;Morten S. Frydensberg ,&nbsp;Ane Fullaondo ,&nbsp;Linda Granlund ,&nbsp;Yhasmine Hamu Azcarate ,&nbsp;Torben F. Hansen ,&nbsp;Emil Høstrup ,&nbsp;Tomi Mäki-Opas ,&nbsp;Luigi Palmieri ,&nbsp;Markku Peltonen ,&nbsp;Valentina Possenti ,&nbsp;Marco Silano ,&nbsp;Gauden Galea","doi":"10.1016/j.lanepe.2025.101553","DOIUrl":"10.1016/j.lanepe.2025.101553","url":null,"abstract":"<div><div>Non-communicable diseases (NCDs) are major drivers of disability, health expenditure, and productivity loss in Europe. Effective surveillance is essential to understand evolving needs, design and evaluate interventions, and ensure accountability. This paper provides a high-level overview of NCD monitoring in Europe, focusing on cardiovascular diseases, cancer, diabetes, chronic respiratory diseases, and major modifiable risk factors. It draws on three complementary sources: the EU Joint Action on Cardiovascular Diseases and Diabetes (JACARDI, 32 countries), the Joint Action on the Prevention of NCDs (JA PreventNCD, 16 countries), and the WHO NCD Country Capacity Survey (2023, 53 WHO European Region Member States). These sources provide a comprehensive assessment of surveillance capacity, infrastructure and gaps, showing that NCD monitoring remains fragmented, underfunded, and limited in equity-sensitive data and policy integration. Strengthening governance, investment, and cross-country collaboration is crucial to build interoperable, and equity-oriented systems supporting evidence-informed decisions, accountability, and the right to health.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"61 ","pages":"Article 101553"},"PeriodicalIF":13.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145747383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}